[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Burcoş T, Popa E, Ivăşcanu A, Ardeleanu C, Zodieru I: [Merkel cell carcinoma]. Chirurgia (Bucur); 2001 Sep-Oct;96(5):509-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine dermal neoplasm.
  • This study is a retrospective outcomes analysis of two cases of MCC with data regarding clinical, histopathological, immunohistochemistry and also surgical, chimio and radiological treatment.
  • MCC is a rare dermal tumors, this tumors are most predictable found on sunexposed sites.
  • Diagnosis is best accomplished by a thorough clinical evaluation coupled with light microscopy and defined panel of immunohistochemical studies which are necessary for the definitive diagnosis of Merkel cell carcinoma (cytokeratins, neuron specific enoiase and chromogranin).
  • MCC is an aggressive tumor with local or locoregionale extension and distant spread by hematogen or lymphatic way.
  • Surgical excision of tumor and regional lymphadenectomy is the first step of treatment completed with radiotherapy and chemotherapy bat in advanced studies the rate of local or distant recidives is high.
  • [MeSH-minor] Aged. Arm. Axilla. Female. Humans. Lymph Node Excision / methods. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731194.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


2. Hung GD, Chen YH, Chen DY, Lan JL: Subcutaneous panniculitis-like T-cell lymphoma presenting with hemophagocytic lymphohistiocytosis and skin lesions with characteristic high-resolution ultrasonographic findings. Clin Rheumatol; 2007 May;26(5):775-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an unusual type of skin lymphoma, characterized by subcutaneous soft tissue infiltration with pleomorphic T-cells and benign macrophages that mimic panniculitis.
  • Hemophagocytic lymphohistiocytosis is a rare but potentially fatal disorder which is thought to result from uncontrolled activation and proliferation of T-cells and excessive activation of macrophages.
  • The fever subsided and the ferritin level declined to normal after treatment with oral steroid and etoposide.
  • However, nonremitting high fever and panniculitis-like skin lesions over her back, arm, lower abdominal wall, and bilateral pretibial regions developed 1 month later.
  • An ultrasound-guided excision biopsy of the nodular lesion over left upper arm was performed and the histopathology showed neoplastic cells with hyperchromatic nucleoli, which extended from deep dermis to subcutaneous fat.
  • The immunochemical stain showed a T-cell lineage of tumor cells.
  • SPTCL was diagnosed and the skin lesions subsided gradually after treatment with anthracycline-based combination chemotherapy.


3. Weisser H, Hartschuh W, Greiner A, Bischof M, Enk A, Helmbold P: [Merkel cell carcinoma--clinically often misjudged]. Dtsch Med Wochenschr; 2007 Jul 30;132(30):1581-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merkel cell carcinoma is a rare, rapidly growing, highly malignant dermal tumor which occurs preferentially on light-exposed skin in advanced age.
  • The course of the disease is frequently characterized by the occurrence of lymph node metastases and local recurrences, even in the first year after removal of the primary tumour.
  • The five-year overall survival rate is only about 65 %, despite rigorous therapy.
  • The excision of the primary tumor is regarded as first-line therapy.
  • Adjuvant chemotherapy can be applied in this stage, as in small-cell bronchial carcinoma.
  • Despite good response to radiatiotherapy and chemotherapy, with at least prolonged recurrence-free intervals, Merkel cell carcinoma is rarely curable at the distant metastasizing stage.
  • Individually defined, aggressive treatment,including radiatiotherapy, may in future considerably improve the prognosis, especially in the early stages of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628844.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


Advertisement
4. Thomison J, McCarter M, McClain D, Golitz LE, Goldenberg G: Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol; 2008 Nov;35(11):1003-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
  • We report a novel histological finding in a dermatofibrosarcoma protuberans (DFSP) after treatment with imatinib mesylate: copious amounts of hyalinized collagen.
  • A 57-year-old female was referred for evaluation and treatment of a 7 x 8 x 10 cm tumor on the right anterior shoulder.
  • Histological evaluation of the incisional biopsy showed a highly cellular dermal neoplasm composed of spindle cells arranged in a storiform pattern with minimal collagen.
  • A CD34 immunohistochemical stain was strongly positive, highlighting atypical spindle cells in the dermis.
  • At the end of therapy, the DFSP decreased in size to 5.5 x 4 x 4 cm.
  • The tumor was excised.
  • Histological evaluation showed a residual dermal neoplasm composed of atypical spindle cells and a copious amount of hyalinized collagen.
  • A procollagen I stain was strongly positive, confirming the presence of abundant collagen in the dermis.
  • A similar finding has been reported in gastrointestinal stromal tumor, which shows deposition of myxohyaline stroma after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Collagen / metabolism. Dermatofibrosarcoma / drug therapy. Hyalin / metabolism. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antigens, CD34 / metabolism. Benzamides. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544062.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9007-34-5 / Collagen
  •  go-up   go-down


5. McMenamin ME, Fletcher CD: Reactive angioendotheliomatosis: a study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol; 2002 Jun;26(6):685-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reactive angioendotheliomatosis (RAE) is a rare condition characterized by cutaneous vascular proliferation that usually occurs in patients with diverse types of coexistent systemic disease.
  • Eleven patients had coexistent systemic disease: renal disease (six patients, including three post renal transplantation); valvular cardiac disease (two patients); one patient each had alcoholic cirrhosis, glioblastoma multiforme (on chemotherapy), and rheumatoid arthritis/polymyalgia rheumatica.
  • All lesions were characterized histologically by a proliferation of capillaries in the dermis, with variably diffuse (seven cases), lobular (six cases), or mixed lobular and diffuse patterns (two cases).
  • Common features included fibrin microthrombi (nine cases), reactive (fasciitis-like) dermal alterations (seven cases), and foci of epithelioid endothelium (four cases).
  • The pathogenesis of this rare disorder is unknown, but it is likely that immunologic factors play a role.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Humans. Immunocompromised Host. Immunohistochemistry. Kidney Diseases / complications. Kidney Diseases / pathology. Male. Middle Aged. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Reactive angioendotheliomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023572.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Lawenda BD, Thiringer JK, Foss RD, Johnstone PA: Merkel cell carcinoma arising in the head and neck: optimizing therapy. Am J Clin Oncol; 2001 Feb;24(1):35-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma arising in the head and neck: optimizing therapy.
  • Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine dermal neoplasm.
  • Because of the limited number of cases described in the literature (approximately 600 to date), statistically significant data regarding treatment are difficult to obtain.
  • This study evaluates cases of head and neck MCC at Naval Medical Center San Diego (NMCSD) and compares the treatment regimens and outcomes from multiple institutions.
  • The records of the NMCSD Tumor Registry were searched for patients with that diagnosis, and supplemental information was retrieved from the Radiation Oncology and Head & Neck Surgery Clinic charts.
  • Subsequent therapy varied among the patients.
  • Survey of the available literature revealed inconsistency in terms of which treatment regimens are optimal.
  • Tumor resections are recommended by most groups to include a 2-cm to 3-cm tumor-free margin around the primary lesion when possible, but this is often difficult to achieve in the head and neck.
  • Data, which do not reach statistical significance, suggest improved outcomes with tumor-free margins.
  • Treatment of the regional draining lymph nodes is also recommended in most series.
  • Prophylactic lymph node dissection or radiation therapy to the nodal chain may decrease local recurrence but does not consistently affect overall survival.
  • Adjuvant chemotherapy is advocated by most groups in the treatment of metastatic disease because MCC is pathologically similar to small-cell lung carcinoma.
  • However, no chemotherapy protocol has been shown to improve survival.
  • Head and neck MCC is a rare and aggressive dermal tumor of neuroendocrine origin that requires multimodality therapy, including surgery, radiation therapy, and possibly adjuvant chemotherapy.
  • Multiinstitutional studies are crucial to obtain sufficiently large populations to investigate and optimize therapy in this disease.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11232947.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


7. Shimura C, Satoh T, Takayama K, Yokozeki H: Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis. J Am Acad Dermatol; 2009 Jul;61(1):126-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis.
  • We describe the development of a cutaneous lymphoproliferative disorder in a patient with rheumatoid arthritis who was treated with methotrexate.
  • Histologic examination revealed large polymorphic atypical cells including Reed-Sternberg-like cells expressing CD20 and CD30 in the dermis and subcutaneous tissues.
  • Tumor cells infiltrated the walls of dermal arterioles, subcutaneous arteries, and veins, leading to the destruction of vascular structures.
  • This case illustrates the rare occurrence of cutaneous vascular involvement in methotrexate-related lymphoproliferative disorder that did not require any specific chemotherapy.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Lymphoproliferative Disorders / chemically induced. Methotrexate / adverse effects

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539849.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Makino S, Mitsutake N, Nakashima M, Saenko VA, Ohtsuru A, Umezawa K, Tanaka K, Hirano A, Yamashita S: DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. J Dermatol Sci; 2008 Sep;51(3):171-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
  • BACKGROUND: Keloid is a benign dermal tumor characterized by proliferation of dermal fibroblasts and overproduction of extracellular matrix (ECM).
  • METHODS: Primary normal and keloid dermal fibroblasts were used for this study.
  • The effect of DHMEQ was evaluated by cell viability, cell growth and type I collagen accumulation.
  • DHMEQ markedly reduced cell proliferation and type I collagen accumulation in keloid fibroblasts.
  • CONCLUSION: The inhibition of NF-kappaB by DHMEQ may be an attractive therapeutic approach for keloids.
  • [MeSH-major] Benzamides / pharmacology. Collagen Type I / metabolism. Cyclohexanones / pharmacology. Keloid / drug therapy. Keloid / metabolism. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Cell Division / drug effects. Cells, Cultured. DNA / metabolism. Fibroblasts / drug effects. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Immunohistochemistry. Transcription Factor RelA / antagonists & inhibitors. Transcription Factor RelA / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406579.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Collagen Type I; 0 / Cyclohexanones; 0 / NF-kappa B; 0 / RELA protein, human; 0 / Transcription Factor RelA; 0 / dehydroxymethylepoxyquinomicin; 9007-49-2 / DNA
  •  go-up   go-down


9. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF: Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis; 2007 Mar;49(3):462-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The clinical challenge for the application of rapamycin and its derivatives as anticancer drugs is the ability to prospectively identify which tumors will be sensitive to mammalian target of rapamycin (mTOR) inhibition.
  • The present study is designed to explore mTOR signaling in peripheral-blood mononuclear cells (PBMCs) from renal transplant recipients with Kaposi sarcoma and ascertain whether it would reflect deregulation of the AKT-mTOR pathway in skin cancer tissue and might help identify which patients would benefit from rapamycin treatment, as well as to monitor their clinical response.
  • METHODS: We measured basal and in vivo stimulated AKT and P70 S6 kinase (P70(S6K)) phosphorylation in PBMCs from 37 cyclosporine A-treated patients, 10 of whom had Kaposi sarcoma, before and 6 months after conversion to rapamycin therapy.
  • Long-term treatment with rapamycin was associated with marked inhibition of basal and stimulated phosphorylation of both AKT and P70(S6K), in parallel with regression of the dermal neoplasm.
  • CONCLUSION: Overactivation of basal P70(S6K) in PBMCs from renal transplant recipients appears to be associated with the presence of Kaposi sarcoma dermal lesions; conversely, kinase inhibition is linked to regression of skin cancer lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Protein Kinases / metabolism. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biomarkers / metabolism. Female. Humans. Kidney Transplantation / adverse effects. Male. Middle Aged. Monocytes / physiology. Patient Selection. Phosphorylation. Predictive Value of Tests. Proto-Oncogene Proteins c-akt / physiology. Ribosomal Protein S6 Kinases, 70-kDa / physiology. Signal Transduction / physiology. TOR Serine-Threonine Kinases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336708.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


10. Sirvent N, Maire G, Pedeutour F: Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer; 2003 May;37(1):1-19
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.
  • Dermatofibrosarcoma protuberans (DP) is a rare, slow-growing, infiltrating dermal neoplasm of intermediate malignancy, made up of spindle-shaped tumor cells often positive for CD34.
  • The preferred treatment is wide surgical excision with pathologically negative margins.
  • Both the rings and linear der(22) contain a specific fusion of COL1A1 with PDGFB.
  • DP is therefore a unique example of a tumor in which (i) the same molecular event occurs either on rings or linear translocation derivatives, (ii) the chromosomal abnormalities display an age-related pattern, and (iii) the presence of the specific fusion gene is associated with the gain of chromosomal segments, probably taking advantage of gene dosage effects.
  • Recent studies have determined the molecular identity of "classical" DP, giant cell fibroblastoma, Bednar tumor, adult superficial fibrosarcoma, and the granular cell variant of DP.
  • It is encouraging that inhibitory effects of the PDGF receptor tyrosine kinase antagonist imatinib mesylate have been demonstrated in vivo; such targeted therapies might be warranted in the near future for treatment of the few DP cases not manageable by surgery.
  • [MeSH-major] Dermatofibrosarcoma / drug therapy. Dermatofibrosarcoma / genetics. Enzyme Inhibitors / therapeutic use. Ring Chromosomes. Skin Neoplasms / drug therapy. Skin Neoplasms / genetics. src-Family Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • Genetic Alliance. consumer health - Ring Chromosomes.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12661001.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.2 / src-Family Kinases
  • [Number-of-references] 109
  •  go-up   go-down


11. Huang PY, Chu CY, Hsiao CH: Multiple eruptive dermatofibromas in a patient with dermatomyositis taking prednisolone and methotrexate. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S81-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibroma (DF) is a common, benign, dermal tumor, often occurring as a single lesion.
  • Multiple eruptive DFs are rare and usually associated with autoimmune diseases, immunosuppressant therapy, or both.
  • We present the case of a 28-year-old woman with dermatomyositis who developed multiple eruptive DFs after undergoing methotrexate and corticosteroid treatment.
  • [MeSH-major] Dermatomyositis / drug therapy. Glucocorticoids / adverse effects. Histiocytoma, Benign Fibrous / chemically induced. Immunosuppressive Agents / adverse effects. Methotrexate / adverse effects. Prednisolone / adverse effects. Skin Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Dermatomyositis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097372.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Zampetti A, Mastrofrancesco A, Flori E, Maresca V, Picardo M, Amerio P, Feliciani C: Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis. Int J Immunopathol Pharmacol; 2009 Oct-Dec;22(4):1067-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis.
  • Hyperproliferation and a marked inflammation in both epidermis and dermis are thought to be driven by interaction of activated type-1 T lymphocytes and antigen-presenting cells and keratinocytes that release several proinflammatory and immunomodulating molecules.
  • The aim of this study is to investigate whether tetrabromofluorecin, commonly know as eosin, a classical compound traditionally topically used in psoriasis for its presumed anti-inflammatory activities, is able to modulate the production of TNF-alpha, IL-6 and IL-8 that are recognized as the most active and characterized cytokines in the pathogenesis of this skin disorder.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Cytokines / metabolism. Dermatologic Agents / pharmacology. Eosine Yellowish-(YS) / pharmacology. Inflammation Mediators / metabolism. Keratinocytes / drug effects. Psoriasis / drug therapy
  • [MeSH-minor] Administration, Topical. Cell Line. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Down-Regulation. Enzyme-Linked Immunosorbent Assay. Humans. Interferon-gamma / metabolism. Interleukins / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074471.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Dermatologic Agents; 0 / Inflammation Mediators; 0 / Interleukins; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down






Advertisement